Similarly, the pharmacologic modulation of GPER resulted in tumor suppression in preclinical models of endometrial [65], nonsmall cell lung carcinoma [77], pancreatic adenocarcinoma [66], and melanoma [64]. This evidence concerns the gene GPER1 and neoplasm.